Coming Soon!

This session will provide an in depth overview of evidence based treatments for opioid use disorder (OUD), with a particular focus on medication treatments for OUD (MOUD) and their use among individuals living with serious mental illness (SMI). This talk will review the pharmacologic profiles of methadone, buprenorphine, and extended release naltrexone, emphasizing clinically relevant interactions with psychotropic medications. We will also explore how acute opioid intoxication or withdrawal can mimic or exacerbate psychotic and affective symptoms, and how this can complicate diagnostic clarity or trigger decompensation in patients with SMI. Additional topics will include coordinating care across mental health and addiction systems, managing co-occurring stimulant or benzodiazepine use, and addressing barriers such as adherence challenges unique to individuals with SMI. Participants will leave with practical guidance to improve patient engagement and deliver integrated treatment for this highly vulnerable population.